Clinical Trial Update: Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating depletion of myeloid-derived suppressor cells to enhance anti-PD-1 therapy in non-small cell lung cancer (Stage IIIB) has terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Non Small Cell Lung Cancer Stage IIIB | Phase 2 | Status: TERMINATED | Results posted: 2020-10-28